Bronchiektasen-Erkrankung: Wann in Betracht ziehen?
Crossref DOI link: https://doi.org/10.1007/s15006-023-2943-7
Published Online: 2023-10-13
Published Print: 2023-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mertsch, Pontus
Ringshausen, Felix C.
Rademacher, Jessica
Text and Data Mining valid from 2023-10-01
Version of Record valid from 2023-10-01
Article History
First Online: 13 October 2023
Interessen-konflikt
: PM: Durchführung klinischer Studien: AstraZeneca, Boehringer-Ingelheim, Insmed.